Article Text

Download PDFPDF
Health-related quality of life in gynecological oncology: Instruments and psychometric properties
  1. W. Boling*,
  2. R. T. Fouladi and
  3. K. Basen-Engquist
  1. * Department of Health and Human Performance, University of Houston
  2. Department of Behavioral Science, University of Texas M.D. Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: Karen Basen-Engquist, Ph.D., M.P.H., University of Texas M.D. Anderson Cancer Center, Department of Behavioral Science, 1515 Holcombe Boulevard – 243, Houston, TX 77030-4095. E-mail: kbasenen{at}mdanderson.org.

Abstract

Quality of life is generally recognized as a subjective, multidimensional concept, which places emphasis on the self-perception and subjective experience of the patient compared to the expectation of an individual's current health state. Health-related quality of life, which encompasses the psychological, physical, and social functioning of patients, has evolved over recent decades into an established treatment outcome in cancer clinical trials. Assessing quality of life as a clinical trial outcome enables clinicians to better address concerns of gynecological oncology patients, but selection of appropriate measurement tools is critical. This article reviews the concepts of reliability and validity, and describes three health-related quality of life instruments, their psychometric properties, and their use in gynecological oncology clinical trials and other cancer research.

  • assessment
  • gynecological cancer
  • quality of life
  • reliability and validity

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • This research was supported, in part, by a cancer prevention fellowship supported by the National Cancer Institute grant R25 CA57730, Robert M. Chamberlain, Ph.D., Principal Investigator.